Crossref
4271 TREAT TO TARGET: NEOADJUVANT ANTI-OBESITY MEDICATION USE IS ASSOCIATED WITH INCREASED ONE-YEAR POSTOPERATIVE WEIGHT LOSS
Surgery for Obesity and Related Diseases · 2026-04 · 22 (4) · S15
DOI: 10.1016/j.soard.2026.02.059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgery for Obesity and Related Diseases, 2026-04.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). 4271 TREAT TO TARGET: NEOADJUVANT ANTI-OBESITY MEDICATION USE IS ASSOCIATED WITH INCREASED ONE-YEAR POSTOPERATIVE WEIGHT LOSS. Surgery for Obesity and Related Diseases, 22(4), S15. https://doi.org/10.1016/j.soard.2026.02.059
Vancouver
4271 TREAT TO TARGET: NEOADJUVANT ANTI-OBESITY MEDICATION USE IS ASSOCIATED WITH INCREASED ONE-YEAR POSTOPERATIVE WEIGHT LOSS. Surgery for Obesity and Related Diseases. 2026;22(4):S15. doi:10.1016/j.soard.2026.02.059
BibTeX
@article{euvimed2026,
title = {4271 TREAT TO TARGET: NEOADJUVANT ANTI-OBESITY MEDICATION USE IS ASSOCIATED WITH INCREASED ONE-YEAR POSTOPERATIVE WEIGHT LOSS},
journal = {Surgery for Obesity and Related Diseases},
year = {2026},
volume = {22},
number = {4},
pages = {S15},
doi = {10.1016/j.soard.2026.02.059}
}
EUVIMED